$BCYP News
Last published 5y ago
- 5y agoBCYPSABSSABSWSAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy CompanyGlobeNewswireCompleted Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol "SABS" SIOUX FALLS, S.D., Oct. 25, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeuti
- 5y agoBCYPBig Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB BiotherapeuticsPR NewswireMIAMI, Oct. 21, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the p
- 5y agoBCYPSAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021Business WireSAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it wil
- 5y agoBCYPSAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19Business WireSAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced that the fi
- 5y agoBCYPSAB Biotherapeutics Appoints Russell Beyer Chief Financial OfficerBusiness WireSAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced the appoint
- 5y agoBCYPSAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19Business WireAdvancement to Phase 3 is major milestone for SAB's unique DiversitAb™ immunotherapy platform that produces fully-human polyclonal antibodies without human donors Both doses of SAB-185 tested in Phase 2 met pre-defined efficacy goal at interim anal
- 5y agoBCYPBig Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB BiotherapeuticsPR NewswireMIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ:BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of st
- 5y agoBCYPSAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19Business Wire$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response Expanded contract scope includes commercial manufacturing and clinical development through licensure for SAB-185 for the
- 5y agoBCYPSAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal InfluenzaBusiness WireTopline data expected in 4Q2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human
- 5y agoBCYPSAB Biotherapeutics to Present at Upcoming September Virtual Investor ConferencesBusiness WireSAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie
- 5y agoBCYPSAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 VariantsBusiness WireFDA findings from research published in bioRxiv using in vitro pseudovirus models confirm SAB-185 broadly neutralizes variants of concern SAB-185 currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial SAB Biotherapeutics (SAB), a clin
- 5y agoBCYPBig Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB BiotherapeuticsPR NewswireMIAMI, July 15, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today reported that Eddie J. Sullivan, PhD, co-founder, president and CEO of SA
- 5y agoBCYPSAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021Business WireSAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced that Eddie J. Sullivan, PhD, co-fo
- 5y agoBCYPSAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS-CoV-2 VariantsBusiness WireFindings Published in Human Vaccines & Immunotherapeutics Show SAB-185 Neutralizes Virus Strains Containing Substitutions Present in Variants of Concern SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy
- 5y agoBCYPBig Cypress Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination with SAB BiotherapeuticsPR NewswireMIAMI, July 7, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp. (NASDAQ:BCYP), (Big Cypress) a blank check company focused on innovative biopharmaceutical firms, today announced the confidential submission with the U.S. Securities and Exchange Commiss
- 5y agoBCYPSAB Biotherapeutics Doses First Participant in Phase 2a Trial of SAB-176 for the Treatment of InfluenzaBusiness WireFirst High-Potency Human Polyclonal Antibody Therapeutic Specifically Designed with the Potential to Treat Rapidly-Mutating Type A and Type B Influenza Viruses SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immuno
- 5y agoBCYPGSAHSNNYTHMAMoore Kuehn Encourages SNNY, GSAH, THMA and BCYP Investors to Contact Law FirmGlobeNewswireNEW YORK, June 24, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
- 5y agoBCYPSAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging DiseasesBusiness WireSAB Biotherapeutics (SAB) has entered into a definitive merger agreement with Big Cypress Acquisition Corp. (NASDAQ:BCYP) and upon closing, the combined company is expected to be listed on NASDAQ Anticipated resources post-transaction will be used
- 5y agoBCYPBig Cypress Acquisition Corp. Announces Separate Trading of its Shares of Common Stock and Redeemable Warrants Commencing February 9, 2021GlobeNewswireMIAMI, FL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced that, commencing February 9, 2021, holders of the units sold in the Company's initial public...
- 5y agoBCYPBig Cypress Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, which Includes Full Exercise of the Underwriters' Over-Allotment OptionGlobeNewswireMIAMI, FL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced today that it closed its initial public offering of 11,500,000 units, which includes the full...
- 5y agoBCYPBig Cypress Acquisition Corp. Announces Pricing of $100 Million Initial Public OfferingGlobeNewswireMIAMI, FL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Big Cypress Acquisition Corp. (the "Company") announced today the pricing of its initial public offering of 10,000,000 units at a price of $10.00 per...